ClinicalTrials.gg
RecruitingNCT06968845Updated Nov 12, 2026

A Phase 2 Study of LTI-03 in Patients With Idiopathic Pulmonary Fibrosis

A Phase 2 interventional study of LTI-03 and Dry Powder Inhaler in Idiopathic Pulmonary Fibrosis (IPF), sponsored by Rein Therapeutics. Recruiting at 48 sites in 7 countries. Open to participants aged 40 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Rein Therapeutics · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Feb 2026; still recruiting 9 months later.
Updated Nov 12, 2026First sites in Bulgaria and RomaniaSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
120
Allocation
Randomized
Ages
40 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States — 37 open to participants now, 51 under way, 8 of them phase 3. Idiopathic Pulmonary Fibrosis · United States.

Planned enrollment
67th of 188
120 · median 61
Started
2026
with 15 others
Phase 2
82 of 236
13 open now
Primary completion
2027-09
later than 24 of 50 live
Registered
218th of 236
by date

Among the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, this one is the 67th largest by planned enrollment of the 188 interventional ones that give a count, is one of 16 that started in 2026, is one of 82 in phase 2, reaches primary completion later than 24 of the 50 other live ones, and was the 218th registered.

Idiopathic Pulmonary Fibrosis

577 studies on the registry are indexed under Idiopathic Pulmonary Fibrosis; 124 are open to participants now.

Browse Idiopathic Pulmonary Fibrosis studies →

Open to participants now

37 of the 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States are open now. Recruiting first, the newest first:

31 more — sign in →

All 37 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 86 Idiopathic Pulmonary Fibrosis studies recruiting now, 56 (65%) set no upper age limit and 8 (9%) stop at 75 or younger; 3 take children under 18; 15 take healthy volunteers.

This study: 40 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 236 studies in Idiopathic Pulmonary Fibrosis with a site in United States, or all of them as a file.
02

Study summary

Rationale: LTI-03 is an experimental medication breathed into the lungs using an inhaler. It is being studied for the treatment of Idiopathic Pulmonary Fibrosis (IPF). IPF is a progressive, fatal lung disease caused by the death of lung cells involved in oxygen uptake and by progressive fibrosis (scarring) of the lungs. As the disease progresses, patients experience loss of lung function and increased breathing problems. LTI-03 is hypothesized to treat IPF by protecting and restoring the function of the oxygen uptake cells and by controlling lung fibrosis which may result in improving lung scarring.

The purpose of this research is to evaluate LTI-03 including: its safety, whether it causes side effects, whether it improves lung scarring, and whether it improves IPF symptoms. LTI-03 will be compared to placebo in patients diagnosed with IPF within the last 5 years. Patients on a stable dose of nintedanib, pirfenidone, or nerandomilast (if available by prescription) may participate.

Trial Design: This is a Phase 2, randomized, double-blind, placebo-controlled, multi-center study that includes a 28-day Screening Period, a 24-week Treatment Period, and 4-week Follow-up Period.

Study Assessments: Up to 9 visits to the study clinic will be required.

Safety and tolerability will be evaluated with the following assessments: physical examination; collection of vital sign data (heart rate, blood pressure, respiratory rate and peripheral oxygen saturation [SpO2] via pulse oximetry); heart data collected by 12-lead electrocardiogram; and collection of blood samples for safety laboratory tests. In addition, participants will be asked about any adverse events (side effects) they have experienced between clinic visits, if they have changed any medications, and if they are able to properly use their study drug inhaler.

Participants will undergo a lung function test (spirometry) at every visit, which will be used to evaluate both safety and efficacy. Another test measuring the diffusion capacity of the lungs for carbon monoxide (DLCO) will be required at Screening only.

Blood samples will also be collected at each visit to measure disease biomarkers. At select visits patients will be asked to complete the Living with Pulmonary Fibrosis questionnaire to evaluate their IPF symptoms. Participants will also undergo a specialized lung scan (HRCT) at Baseline and at the End of Treatment to measure changes in lung fibrosis.

Interventions: LTI-03 and placebo are provided in powder-filled capsules that participants will self- administer using an inhaler. Placebo capsules look like LTI-03 capsules but have no active ingredients. Approximately 120 participants will be randomly assigned in a blinded manner to one of study drug treatment groups.

03

Conditions studied

  • Idiopathic Pulmonary Fibrosis (IPF)

Keywords

  • Idiopathic Pulmonary Fibrosis
  • Antifibrotic
  • Interstitial Lung Disease
04

Who can participate

Ages eligible
40 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Male or female age 40 years or older.
  2. Willing and able to provide written .
  3. Diagnosis of IPF within 5 years of Screening as confirmed by a centrally read HRCT of the chest as defined by the ATS/ERS/JRS/ALAT guideline. HRCT lung fibrosis by central read during screening must involve ≥ 10% of the lung and be greater than emphysema involvement of the lung.
  4. Forced vital capacity (FVC) percent predicted ≥ 45% at Screening.
  5. Diffusion capacity of the lungs for carbon monoxide (DLCO), -corrected percent predicted ≥ 30% within 8 weeks prior to Randomization.
  6. Participants receiving nintedanib, pirfenidone, or nerandomilast (where approved for marketing) for IPF treatment must have been on a stable prescribed dose for at least 12 weeks prior to Randomization.
  7. Participants who previously received nintedanib, pirfenidone, or nerandomilast must have discontinued treatment at least 8 weeks prior to Randomization.
  8. Able to adequately self-administer study drug using the protocol-specified inhaler device.

Exclusion criteria

Exclusion Criteria:

  1. (FEV1)/FVC \< 0.7 at Screening.
  2. Use of N-acetyl cysteine or other supplements including but not limited to quercetin, omega-3 fatty acids, dehydroepiandrosterone, polyphenols, and phytochemicals within 7 days prior to Randomization and through Week 24.
  3. Use of systemic at doses > 10 mg/day of prednisone or equivalent within 28 days prior to Randomization.
  4. Active smoker.
  5. Pulmonary exacerbation within 3 months prior to Screening.
  6. Febrile pulmonary illness requiring antibiotic treatment within 28 days prior to Randomization.
  7. Participation in a clinical study or treatment with an drug or device within 28 days of the Screening Visit (or 5 half-lives of the investigational agent, whichever is longer).
  8. History or evidence at Screening of significant renal impairment with estimated (eGFR) \< 30 mL/min/1.73m2.
  9. History or evidence at Screening of significant hepatic impairment with > 3 mg/dL (> 51.3 μmol/L) and albumin \< 2.8 g/dL (\<28 g/L) and PT prolongation > 6 sec or > 2.3 while not on anticoagulant medication.
  10. Active or history of within 5 years prior to Randomization, with the exception of localized nonmetastatic basal or squamous cell carcinoma of the skin, in situ carcinoma of the cervix, or prostate cancer.
  11. Serious or active medical or psychiatric condition which, in the opinion of the Investigator, may interfere with treatment, assessment, or compliance with the protocol; or an expected survival of less than 24 weeks.

    and Pregnancy

  12. Positive pregnancy test in female participants of (defined below).
  13. Female participants who are lactating.
  14. Females of childbearing potential (FOCBP) and men with partners of childbearing potential who do not agree to use an acceptable form of contraception for the duration of study treatment and for at least 90 days after the last dose of study drug. Male participants who do not agree to refrain from donating sperm during this same period.
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
120 participants (estimated)

Study arms

  • Experimental
    (1) 2.5 mg LTI-03 capsule BID

    Caveolin-1-Scaffolding-Protein-Derived Peptide

    Drug: LTI-03 · Device: Dry Powder Inhaler

  • Experimental
    (2) 2.5 mg LTI-03 capsules BID

    Caveolin-1-Scaffolding-Protein-Derived Peptide

    Drug: LTI-03 · Device: Dry Powder Inhaler

  • Placebo comparator
    (1) Placebo capsule BID

    Lactose powder

    Device: Dry Powder Inhaler · Drug: Placebo

  • Placebo comparator
    (2) Placebo capsules BID

    Lactose powder

    Device: Dry Powder Inhaler · Drug: Placebo

Interventions

  • DrugLTI-03

    Caveolin-1-Scaffolding-Protein-Derived Peptide

  • DeviceDry Powder Inhaler

    Plastiape Monodose RS01 Model 7

  • DrugPlacebo

    Lactose powder

06

What researchers measure

Primary outcomes

  1. Safety and Tolerability as measured by the incidence of treatment-emergent adverse events (TEAEs)

    Time frame: Day 1 through Week 24

Secondary outcomes

  1. Change from baseline in forced vital capacity (FVC)

    Time frame: Day 1 through Week 24

  2. Change from baseline in percent predicted FVC

    Time frame: Day 1 through Week 24

  3. Change from baseline in lung fibrosis measured by high resolution computed tomography (HRCT)

    Time frame: Day 1 through Week 24

07

Study locations

46 of 48 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

4 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2026 (actual). Primary completion is estimated for Sep 2027, 19 months after the start.

Of 63 industry-sponsored phase 2 interventional studies under Idiopathic Pulmonary Fibrosis, half reached primary completion within 26 months of starting (the median), counting those still running; a quarter within 20 and three quarters within 45. This study's planned 19 months is below that.

Counting every sponsor, half of 76 studies reached it within 30 months; a quarter within 21 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2025
First posted
May 13, 2025
StartActual
Feb 2, 2026
Primary completionEst.
Sep 30, 2027
CompletionEst.
Dec 31, 2027
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
12 sites added — first sites in Bulgaria and Romania. 6 sites changed recruiting status (6 now recruiting)
Show 6 sites
  • Diagnostic- Consultative Center Convex EOOD · Sofia, BulgariaNot yet recruiting→Recruiting
  • Prywatny Gabinet Lekarski Ginekologia i Poloznictwo Ultrasonografia Prof. Jacek Suzin · Lodz, PolandNot yet recruiting→Recruiting
  • EMed Centrum Uslug Medycznych · Rzeszów, PolandNot yet recruiting→Recruiting
  • FutureMeds Bucharest - PPDS · Bucharest, RomaniaNot yet recruiting→Recruiting
  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova · Craiova, RomaniaNot yet recruiting→Recruiting
  • MCpulmo-2018 Ltd · Haskovo, BulgariaNot yet recruiting→Recruiting
Show 12 added (4 Romania, 3 Bulgaria, 2 Poland, 1 United States, 1 Australia, 1 United Kingdom)
  • Atrium Health Wake Forest School of Medicine · Winston-Salem, United States
  • Lung Research Victoria · Melbourne, Australia
  • MCpulmo-2018 Ltd · Haskovo, Bulgaria
  • Diagnostic- Consultative Center Convex EOOD · Sofia, Bulgaria
  • Diagnostic- Consultative Center Convex EOOD · Sofia, Bulgaria
  • Prywatny Gabinet Lekarski Ginekologia i Poloznictwo Ultrasonografia Prof. Jacek Suzin · Lodz, Poland
  • EMed Centrum Uslug Medycznych · Rzeszów, Poland
  • FutureMeds Bucharest - PPDS · Bucharest, Romania
  • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova · Craiova, Romania
  • AI Clinical Research · Sibiu, Romania
  • Sf. Ioan cel Nou Emergency County Hospital · Suceava, Romania
  • University College Hospital - PPDS · London, United Kingdom
across 3 updates, Oct 16, 2026 – Nov 12, 2026
Site contacts
Changed at 9 sites. See the sites
Show 9 sites
  • Indiana University · Indianapolis, United StatesContact c•••@iuhealth.org→e•••@iuhealth.org
  • University of Cincinnati Medical Center · Cincinnati, United StatesContact j•••@ucmail.uc.edu→g•••@ucmail.uc.edu
  • Medical University of South Carolina · Charleston, United StatesContact w•••@musc.edu→p•••@musc.edu
  • Royal Devon and Exeter Hospital · Exeter, United KingdomContact a•••@nhs.net→r•••@nhs.net
  • Royal Brompton Hospital · London, United KingdomContact m•••@nhs.net→J•••@nhs.net
  • University of Utah · Salt Lake City, United StatesContact c•••@hsc.utah.edu→j•••@hsc.utah.edu
  • Salus Aegroti Praktyka Lekarska dr n. med. Grzegorz Gąsior · Sosnowiec, PolandContact k•••@pulmag.pl→k•••@pulmag.pl
  • University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact none listed→a•••@med.unc.edu
  • Instytut Gruzlicy i Chrob Pluc · Warsaw, PolandContact added k•••@igichp.edu.pl
across 3 updates, Oct 16, 2026 – Nov 3, 2026
Show all 4 updates
  1. Nov 12, 2026
    MCpulmo-2018 Ltd is now Recruiting
  2. Nov 3, 2026
    6 sites changed recruiting status (6 now recruiting)
    Show 6 sites
    • Diagnostic- Consultative Center Convex EOOD · Sofia, BulgariaNot yet recruiting→Recruiting
    • Diagnostic- Consultative Center Convex EOOD · Sofia, BulgariaNot yet recruiting→Recruiting
    • Prywatny Gabinet Lekarski Ginekologia i Poloznictwo Ultrasonografia Prof. Jacek Suzin · Lodz, PolandNot yet recruiting→Recruiting
    • EMed Centrum Uslug Medycznych · Rzeszów, PolandNot yet recruiting→Recruiting
    • FutureMeds Bucharest - PPDS · Bucharest, RomaniaNot yet recruiting→Recruiting
    • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova · Craiova, RomaniaNot yet recruiting→Recruiting
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of North Carolina at Chapel Hill · Chapel Hill, United StatesContact none listed→a•••@med.unc.edu
    • Instytut Gruzlicy i Chrob Pluc · Warsaw, PolandContact added k•••@igichp.edu.pl
  3. Nov 2, 2026
    Site contacts Changed at 2 sites. See the sites
    Show 2 sites
    • University of Utah · Salt Lake City, United StatesContact c•••@hsc.utah.edu→j•••@hsc.utah.edu
    • Salus Aegroti Praktyka Lekarska dr n. med. Grzegorz Gąsior · Sosnowiec, PolandContact k•••@pulmag.pl→k•••@pulmag.pl
  4. Oct 16, 2026
    12 sites added — first sites in Bulgaria and Romania
    Show 12 added (4 Romania, 3 Bulgaria, 2 Poland, 1 United States, 1 Australia, 1 United Kingdom)
    • Atrium Health Wake Forest School of Medicine · Winston-Salem, United States
    • Lung Research Victoria · Melbourne, Australia
    • MCpulmo-2018 Ltd · Haskovo, Bulgaria
    • Diagnostic- Consultative Center Convex EOOD · Sofia, Bulgaria
    • Diagnostic- Consultative Center Convex EOOD · Sofia, Bulgaria
    • Prywatny Gabinet Lekarski Ginekologia i Poloznictwo Ultrasonografia Prof. Jacek Suzin · Lodz, Poland
    • EMed Centrum Uslug Medycznych · Rzeszów, Poland
    • FutureMeds Bucharest - PPDS · Bucharest, Romania
    • Spitalul Clinic de Boli Infectioase si Pneumoftiziologie Dr. Victor Babes Craiova · Craiova, Romania
    • AI Clinical Research · Sibiu, Romania
    • Sf. Ioan cel Nou Emergency County Hospital · Suceava, Romania
    • University College Hospital - PPDS · London, United Kingdom
    Site contacts Changed at 5 sites. See the sites
    Show 5 sites
    • Indiana University · Indianapolis, United StatesContact c•••@iuhealth.org→e•••@iuhealth.org
    • University of Cincinnati Medical Center · Cincinnati, United StatesContact j•••@ucmail.uc.edu→g•••@ucmail.uc.edu
    • Medical University of South Carolina · Charleston, United StatesContact w•••@musc.edu→p•••@musc.edu
    • Royal Devon and Exeter Hospital · Exeter, United KingdomContact a•••@nhs.net→r•••@nhs.net
    • Royal Brompton Hospital · London, United KingdomContact m•••@nhs.net→J•••@nhs.net

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06968845
Lead sponsor
Rein Therapeutics
Responsible party
Sponsor
First posted
May 13, 2025
Start date
Feb 2, 2026
Primary completion
Sep 30, 2027 (estimated)
Completion
Dec 31, 2027 (estimated)
Last update
Nov 12, 2026

Study contacts

Steven A. Shoemaker, MD
Contact
sshoemaker@nicosof.com
720-560-2167
Shawna H. Evans
Contact
sevans@reintx.com

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: LTI-03

Start the discussion